<i>KEL6</i> and <i>KEL7</i> genotyping with sequence‐specific primers

Renoud, Keli J.; Barracchini, Kathleen C.; Byrne, Karen M.; Adams, Sharon; Pickett, Angela; Caruccio, Lorraine; Stroncek, David F.

doi:10.1111/j.1537-2995.2006.00937.x

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately two‐thirds of these publications, however, would outright qualify as “molecular.” 29‐80 Many molecular immunohematology publications addressed routine clinical applications 29‐39 and clinical consequences 36‐43 . A large number of publications on basic transfusion medicine research topics 43‐76 document the need to explore genetic features and to collate the allelic variety present within and among the various populations worldwide 29,42,44,46‐54,71,73 . A Workshop on Molecular Methods in Immunohematology was sponsored in September 2006 by Food and Drug Administration (FDA)/Center for Biologics Evaluation and Research, Department of Health and Human Services Office of the Secretary/Office of Public Health and Science, National Institutes of Health/National Heart, Lung, and Blood Institute.…”

Section: Molecular Methods In Immunohematologymentioning

confidence: 99%

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Denomme

Flegel

2008

Transfusion

View full text Add to dashboard Cite

Lessons from more than 100 years of immunohematology exemplify that many critical discoveries were made serendipitously and their more rapid implementation could have benefited transfusion recipients and pregnancies. Constituents of blood that are not essential for the attempted therapeutic benefit of a transfusion are largely removed from today's blood products. We are now moving on to avoid unnecessary exposure to potentially harmful constituents of the therapeutically required cells, like blood group antigens that are foreign to the patient. Cost efficacy needs to be kept in mind but may eventually prove much better than anticipated, once hidden benefits are captured, as we show by examples from past immunohematologic developments. Here, we detail clinical applications for molecular immunohematology advances including "dry-matching" that will improve transfusion outcomes and argue for their widespread implementation by rapid timelines through standards of practice.

show abstract

Section: Molecular Methods In Immunohematologymentioning

confidence: 99%

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Denomme

Flegel

2008

Transfusion

View full text Add to dashboard Cite

show abstract

“…High-through put RBC antigen genotyping assays use duplicate probes to detect the same allele with both SNPs, but Renoud et al (25) demonstrated that probes recognizing KEL at 2019 bp cannot be used to confirm KEL*6/KEL*7 genotyping results. These authors showed that in some Afro-American people the gene encoding the KEL7 antigen is different to the one that was originally described, presenting a cytosine at the 1790 bp position and guanine instead of an adenine in the 2019 position.…”

Section: Discussionmentioning

confidence: 99%

An easy and efficient strategy for KEL genotyping in a multiethnic population

Arnoni¹,

Muniz²,

Paula³

et al. 2013

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

BackgroundThe Kell blood group system expresses high and low frequency antigens with the most important in relation to transfusion including the antithetic KEL1 and KEL2; KEL3 and KEL4; KEL6 and KEL7 antigens. Kell is a clinically relevant system, as it is highly immunogenic and anti-KEL antibodies are associated with hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. Although required in some situations, Kell antigen phenotyping is restricted due to technical limitations. In these cases, molecular approaches maybe a solution. This study proposes three polymerase chain reaction genotyping protocols to analyze the single nucleotide polymorphisms responsible for six Kell antithetic antigens expressed in a Brazilian population. MethodsDNA was extracted from 800 blood donor samples and three polymerase chain reaction-restriction fragment length polymorphism protocols were used to genotype the KEL*1/KEL*2, KEL*3/KEL*4 and KEL*6/KEL*7 alleles. KEL*3/KEL*4 and KEL*6/KEL*7 genotyping was standardized using the NlaIII and MnlI restriction enzymes and validated using sequencing. KEL*1/KEL*2 genotyping was performed using a previously reported assay. ResultsKEL genotyping was successfully implemented in the service; the following distribution of KEL alleles was obtained for a population from southeastern Brazil: KEL*1 (2.2%), KEL*2 (97.8%), KEL*3 (0.69%), KEL*4 (99.31%), KEL*6 (2.69%) and KEL*7 (97.31%). Additionally, two individuals with rare genotypes, KEL*1/KEL*1 and KEL*3/KEL*3, were identified. ConclusionKEL allele genotyping using these methods proved to be reliable and applicable to predict Kell antigen expressions in a Brazilian cohort. This easy and efficient strategy can be employed to provide safer transfusions and to help in rare donor screening.

show abstract

“…Unrelated to projects during the SBB program, 11 former SBB graduates (20%) authored 20 publications, 20,21,24,29,32,[50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65] including two SBB graduates who contributed to current SBB student publications. 20,24 Two SBB graduates were co-authors on 12 of the 20 publications, 20,21,24,51-54,56,57,60-62 and three SBB graduates were co-authors of one publication. 59…”

Section: Publications After Graduationmentioning

confidence: 99%

An outcome-based review of an accredited Specialist in Blood Banking (SBB) program: 25 years and counting

2020

View full text Add to dashboard Cite

Specialist in Blood Banking (SBB) programs play an important role in preparing technologists to become leaders and contributors to the field of transfusion medicine through dedicated education and training. The SBB program at the National Institutes of Health (NIH) Clinical Center has graduated 55 students since 1994 with an overall pass rate of 96 percent for the American Society for Clinical Pathology (ASCP) SBB examination. Graduates hold positions in a variety of transfusion medicine-related fields, with hospitals, blood centers, and Immunohematology Reference Laboratories being the most common categories of employer. Projects completed as part of the program added to transfusion medicine knowledge as evidenced by publications and awards. Almost half of all projects completed led to publications (49%), and greater than 50 percent of submissions have been selected for the AABB Future Leaders Scholarship (previously known as AABB Fenwal Scholarship Award). The students have completed over 40 program value-added opportunities. This information was available for retrieval and review. In this review, we analyzed data for the last 25 years from the SBB program at the NIH Clinical Center on program statistics, student accomplishments (such as publications in peer-reviewed journals), program value-added opportunities (such as other publications and audits performed with our Quality Assurance office), and job procurement. The collected, reviewed, and organized data provided a useful internal self-assessment to review the history of our program and head into the future. Immunohematology 2020;36:7-13.

show abstract

KEL6 and KEL7 genotyping with sequence‐specific primers

Cited by 4 publications

References 13 publications

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time

An easy and efficient strategy for KEL genotyping in a multiethnic population

An outcome-based review of an accredited Specialist in Blood Banking (SBB) program: 25 years and counting

Contact Info

Product

Resources

About